Formulation and in vivo evaluation of a self-microemulsifying drug delivery system of dutasteride

Drug Research

Volumn 63, Issue 4, 2013, Pages 203-209

  Choo, G H ^a   Park, S J ^a   Hwang, S J ^b   Kim, M S ^a  

^a Inje University   (South Korea)

^b Yonsei University   (South Korea)

Author keywords

bioavailability; dutasteride; pharmacokinetics; self microemulsifying drug delivery system

Indexed keywords

ACYLGLYCEROL; DUTASTERIDE; GLYCEROL OLEATE; GLYCERYL MONOLINOLEATE; GLYCOL CAPRYLATE; LINOLEOYL MACROGOLGLYCERIDE; MEDIUM CHAIN TRIACYLGLYCEROL; OLEOYL MACROGOLGLYCERIDE; PROPYLENE GLYCOL; PROPYLENE GLYCOL DICAPRYLATE; PROPYLENE GLYCOL MONOCAPRYLATE; PROPYLENE GLYCOL MONOLAURATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; SELF MICROEMULSIFYING DRUG DELIVERY SYSTEM; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84877765534     PISSN: 21949379     EISSN: 21949387     Source Type: Journal    
DOI: 10.1055/s-0033-1334965     Document Type: Article

References (34)

1. Gisleskog P. O., Hermann D., Hammarlund-Udenaes M. et al. The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination. Br J Clin Pharmacol: 1999; 47 53 58 (Pubitemid 29043165)
2. Evans H. C., Goa K. L. Dutasteride. Drugs Aging: 2003; 20 905 916 (Pubitemid 37340283)
3. Andriole G., Bruchovsky N., Chung L. W. et al. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol: 2004; 172 1399 1403 (Pubitemid 39249729)
4. U.S. Food Drug Administration "Application Number: 21-319.o": http://www.accessdata.fda.gov/drugsatfda-docs/nda/2001/21319-Duagen-biopharmr- P1.pdf cited 20 Dec: 2012
5. Baek I. H., Kim M. S. Improved supersaturation and oral absorption of dutasteride by amorphous solid dispersions. Chem Pharm Bull: 2012; 60 1468 1473
6. Park S. J., Choo G. H., Hwang S. J. et al. Quality by Design: Screening of Critical Variables and Formulation Optimization of Eudragit E Nanoparticles Containing Dutasteride. Arch. Pharm Res: 2013; http://dx.doi.org/10.1007/s12272- 013-0064-z
7. Kim C. K., Park J. S. Solubility enhancers for oral drug delivery: can chemical structure manipulation be avoided? Am J Drug Deliv: 2005; 2 113 130
8. Gursoy R. N., Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother: 2004; 58 173 182 (Pubitemid 38479922)
9. Patel D., Sawant K. K. Self micro-emulsifying drug delivery system: formulation development and biopharmaceutical evaluation of lipophilic drugs. Curr Drug Deliv: 2009; 6 419 424
10. Subramanian N., Ray S., Ghosal S. K. et al. Formulation design of self-microemulsifying drug delivery systems for improved oral bioavailability of celecoxib. Biol Pharm Bull: 2004; 27 1993 1999 (Pubitemid 41701577)
11. Basalious E. B., Shawky N., Badr-Eldin S. M. SNEDDS containing bioenhancers for improvement of dissolution and oral absorption of lacidipine. I: development and optimization. Int J Pharm: 2010; 391 203 211
12. Pawar S. K., Vavia P. R. Rice germ oil as multifunctional excipient in preparation of self-microemulsifying drug delivery system (SMEDDS) of tacrolimus. AAPS PharmSciTech: 2012; 13 254 261
13. Dixit A. R., Rajput S. J., Patel S. G. Preparation and bioavailability assessment of SMEDDS containing valsartan. AAPS PharmSciTech: 2010; 11 314 321
14. Vonderscher J., Meinzer A. Rationale for the development of Sandimmune Neoral. Transplant Proc: 1994; 26 2925 2927 (Pubitemid 24329369)
15. Kohli K., Chopra S., Dhar D. et al. Self-emulsifying drug delivery systems: an approach to enhance oral bioavailability. Drug Discov Today: 2010; 15 958 965
16. Thi T. D., Van Speybroeck M., Barillaro V. et al. Formulate-ability of ten compounds with different physicochemical profiles in SMEDDS. Eur J Pharm Sci: 2009; 38 479 488
17. Awotwe-Otoo D., Zidan A. S., Rahman Z. et al. Evaluation of anticancer drug-loaded nanoparticle characteristics by nondestructive methodologies. AAPS PharmSciTech: 2012; 13 611 622
18. Kaul G., Huang J., Chatlapalli R. et al. Quality-by-design case study: investigation of the role of poloxamer in immediate-release tablets by experimental design and multivariate data analysis. AAPS PharmSciTech: 2011; 12 1064 1076
19. Jin S. J., Yoo Y. H., Kim M. S. et al. Paroxetine hydrochloride controlled release POLYOX matrix tablets: screening of formulation variables using Plackett-Burman screening design. Arch Pharm Res: 2008; 31 399 405
20. Kim M. S., Kim J. S., You Y. H. et al. Development and optimization of a novel oral controlled delivery system for tamsulosin hydrochloride using response surface methodology. Int J Pharm: 2007; 341 97 104
21. Lee Y. L., Kim M. S., Park M. Y. et al. Quality by design: understanding the formulation variables and optimization of metformin hydrochloride 750 mg sustained release tablet by Box-Behnken design. J Pharm Invest: 2012; 42 213 220
22. El-Malah Y., Nazzal S., Khanfar N. M. D-optimal mixture design: optimization of ternary matrix blends for controlled zero-order drug release from oral dosage forms. Drug Dev Ind Pharm: 2006; 32 1207 1218 (Pubitemid 44721735)
23. Eriksson L., Johansson E., Wikström C. Mixture design - design generation, PLS analysis, and model usage. Chemometr Intell Lab: 1998; 43 1 24 (Pubitemid 28481343)
24. Mura P., Furlanetto S., Cirri M. et al. Optimization of glibenclamide tablet composition through the combined use of differential scanning calorimetry and d-optimal mixture experimental design. J Pharm Biomed Anal: 2005; 37 65 71 (Pubitemid 40138717)
25. Ramakrishna N. V., Vishwottam K. N., Puran S. et al. Selective and rapid liquid chromatography - tandem mass spectrometry assay of dutasteride in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci: 2004; 809 117 124 (Pubitemid 38998428)
26. Singh A. K., Chaurasiya A., Singh M. et al. Exemestane loaded self-microemulsifying drug delivery system (SMEDDS): development and optimization. AAPS PharmSciTech: 2008; 9 628 634
27. Zhang L., Zhu W., Yang C. et al. A novel folate-modified self-microemulsifying drug delivery system of curcumin for colon targeting. Int J Nanomedicine: 2012; 7 151 162
28. Yan Y. D., Kim J. A., Kwak M. K. et al. Enhanced oral bioavailability of curcumin via a solid lipid-based self-emulsifying drug delivery system using a spray-drying technique. Biol Pharm Bull: 2011; 34 1179 1186
29. Myers R. H., Montgomery D. C. Response surface methodology: process and product optimization using designed experiments. John Wiley & Sons New York: 2002; 273 286
30. Pouton C. W. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur J Pharm Sci: 2000; 11 S93 S98
31. Porter C. J., Trevaskis N. L., Charman W. N. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov: 2007; 6 231 248 (Pubitemid 46344627)
32. Cornaire G., Woodley J., Hermann P. et al. Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int J Pharm: 2004; 278 119 131 (Pubitemid 38670443)
33. Sha X., Yan G., Wu Y. et al. Effect of self-microemulsifying drug delivery systems containing Labrasol on tight junctions in Caco-2 cells. Eur J Pharm Sci: 2005; 24 477 486 (Pubitemid 40387261)
34. Dahan A., Hoffman A. The effect of different lipid based formulations on the oral absorption of lipophilic drugs: The ability of in vitro lipolysis and consecutive ex vivo intestinal permeability data to predict in vivo bioavailability in rats. Euro J Pharm Biopharm: 2007; 67 96 105 (Pubitemid 46991342)